Mira Pharmaceuticals Inc. has announced progress in its acquisition of SKNY Pharmaceuticals Inc. The company is finalizing the necessary regulatory filings and expects to submit the required documentation to the U.S. Securities and Exchange Commission in the coming weeks. SKNY's lead development candidate, SKNY-1, focuses on smoking cessation and obesity treatment, targeting CB1, CB2, and MAO-B receptors. This acquisition is part of Mira's strategy to expand its portfolio and explore therapeutic areas with significant unmet needs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.